Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.9K
Overview
51.9K
Types of Toxins01:36

Types of Toxins

3.7K
Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
3.7K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Self-Evaluation: Self-Enhancement and Self-Verification03:00

Self-Evaluation: Self-Enhancement and Self-Verification

5.8K
Social psychologists have documented that feeling good about ourselves and maintaining positive self-esteem is a powerful motivator of human behavior (Tavris & Aronson, 2008). In the United States, members of the predominant culture typically think very highly of themselves and view themselves as good people who are above average on many desirable traits (Ehrlinger, Gilovich, & Ross, 2005). Often, our behavior, attitudes, and beliefs are affected when we experience a threat to our...
5.8K
Bioavailability Enhancement: Drug Solubility Enhancement01:16

Bioavailability Enhancement: Drug Solubility Enhancement

278
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
278
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

216
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
216

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Manufacture of the first FDA-approved batches of 900 kilodalton crystalline type a botulinum toxin for clinical use: a personal remembrance.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Enteric botulinum neurotoxins facilitate infection by <i>Salmonella</i> and <i>Shigella</i>.

Science advances·2026
Same author

Korean botulinum toxins.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Iatrogenic botulism: a risk for botulinum toxin's medical use?

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Botulinum neurotoxin Light Chain/A1 uses fast synaptic vesicle cycling to cleave plasma membrane bound SNAP-25.

Communications biology·2025
Same author

A Data-driven Age-related Macular Degeneration Severity Scoring System Leveraging the AREDS Studies and Clinical Electronic Medical Records.

Ophthalmology·2025
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026
Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026
See all related articles

Related Experiment Video

Updated: Feb 16, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.5K

Enhancing toxin-based vaccines against botulism.

Amanda Przedpelski1, William H Tepp2, Madison Zuverink1

  • 1Medical College of Wisconsin, 8701 W Watertown Plank Rd., Microbiology and Immunology, Milwaukee, WI 53226, United States.

Vaccine
|January 9, 2018
PubMed
Summary
This summary is machine-generated.

A novel vaccine candidate, M-BoNT/A1W, effectively protects against botulism by neutralizing botulinum neurotoxins (BoNT). This engineered toxin, with reduced toxicity and receptor binding, elicits a potent immune response for potential use against toxin-mediated diseases.

Keywords:
Botulinum neurotoxinBotulinum neurotoxin A1Botulinum neurotoxin A2BotulismELISAVaccine

More Related Videos

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines
05:39

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Published on: October 30, 2018

12.7K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K

Related Experiment Videos

Last Updated: Feb 16, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.5K
Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines
05:39

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Published on: October 30, 2018

12.7K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K

Area of Science:

  • Toxicology
  • Immunology
  • Vaccine Development

Background:

  • Botulinum neurotoxins (BoNT) are highly toxic proteins with no approved vaccines for botulism.
  • BoNTs consist of a light chain (LC) and a heavy chain (HC) with distinct functional domains.

Purpose of the Study:

  • To evaluate engineered botulinum neurotoxin variants as potential vaccine candidates against botulism.
  • To assess the safety and immunogenicity of detoxified and receptor-binding-impaired BoNT/A1 constructs.

Main Methods:

  • Engineered full-length BoNT/A1 with mutations to eliminate catalytic activity (M-BoNT/A1) and reduce receptor binding (M-BoNT/A1W).
  • Vaccinated mice with engineered BoNT variants and challenged them with native BoNT/A1 or BoNT/A2.
  • Assessed neutralizing antibody responses in mouse sera and on cultured neuronal cells.

Main Results:

  • M-BoNT/A1W vaccination provided significant protection against high doses of BoNT/A1 challenge.
  • Both M-BoNT/A1 and M-BoNT/A1W equally protected against BoNT/A2 challenge.
  • Vaccination elicited potent neutralizing antibody responses targeting different BoNT domains, effective in both mouse models and cell-based assays.

Conclusions:

  • The engineered M-BoNT/A1W demonstrates a promising vaccine strategy against botulism.
  • This approach, involving modified toxins with impaired functions, can elicit robust protective immunity.
  • The study supports the potential of using engineered toxins as vaccines for botulism and other toxin-mediated diseases.